Q4 2024 Scholar Rock Holding Corp Earnings Call Transcript
Key Points
- Scholar Rock Holding Corp (SRRK) is on track to launch apitegromab, a muscle-targeted therapy for SMA, in the US in 2025, with plans to expand to the EU in 2026.
- The SAPPHIRE study showed that apitegromab plus standard of care delivered clinically meaningful and statistically significant improvements in motor function for SMA patients.
- The company is making significant progress in its cardiometabolic program, with plans to share top-line data from the EMBRAZE study in Q2 2025.
- Scholar Rock Holding Corp (SRRK) has a strong commercial strategy, including the 'Life Takes Muscle' campaign, to prepare the market for the new treatment paradigm in SMA.
- The company is actively engaging with payers and stakeholders to ensure access and coverage for apitegromab, reflecting its value in treating SMA.
- There is still uncertainty around the regulatory acceptance of body composition changes as a primary endpoint for the cardiometabolic program.
- The competitive landscape for weight loss therapies is intensifying, which may impact the commercial success of SRK-439.
- The company has not yet disclosed pricing details for apitegromab, which could affect market acceptance and payer negotiations.
- The development of additional neuromuscular indications for apitegromab is still in the early stages, with no specific timelines provided.
- The potential impact of preserving lean muscle mass on overall weight loss with GLP-1 receptor therapies remains uncertain, which could affect the perceived value of SRK-439.
Good morning and welcome to Scholar Rock's fourth quarter of financial results and business update call. (Operator Instructions)
Please note this event is being recorded. Before we begin, I'd like to point out that we'll be making various statements about Scholar Rock's expectations, plans, and prospects that constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any future date.
I encourage you to go to the Investors and Media section of our website to find our most up-to-date SEC statements and filings. A recording of today's event will also be available on our website should you want to re-watch at a later date.
I will now turn the conference over to Jay Backstrom, President and CEO of Scholar Rock. Mr. Jay, please go ahead.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
